您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

Non-clinical Research-used
Medicine Sample Provider
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 眼科药物->细菌性结膜炎
处方药:处方药
包装规格: 28mg/cap 56caps/pack
计价单位:
  点击放大  
生产厂家中文参考译名:
Mylan Specialty L.P.
生产厂家英文名:
Mylan Specialty L.P.
该药品相关信息网址1:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4b5bb1f-e158-4ac1-9c35-e98a416c743a
原产地英文商品名:
TOBI® Podhaler® 28mg/cap 56caps/pack
原产地英文药品名:
tobramycin inhalation powder
中文参考商品译名:
TOBI® Podhaler® 28毫克/胶囊 56胶囊/盒
中文参考药品译名:
tobramycin inhalation powder
原产地国家批准上市年份:
2021/09/01
英文适应病症1:
keratoconjunctivitis
英文适应病症2:
bacterial blepharitis
英文适应病症3:
bacterial conjunctivitis
临床试验期:

中文适应病症参考翻译1:
角膜结膜炎
中文适应病症参考翻译2:
细菌性睑缘炎
中文适应病症参考翻译3:
细菌性结膜炎
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件(202372419585116.pdf)文件为准
---------------------------------------------------------------
部分中文 处方资料(仅供参考)

tobramycin inhalation powder

药品介绍
TOBI® Podhaler®是一种具有均匀脂质核的脂囊泡,被广泛应用于小分子药物和核酸递送。

适应症
TOBI Podhaler 适用于治疗铜绿假单胞菌囊性纤维化患者。

用法用量
TOBI Podhaler胶囊不得吞咽,因为无法在肺部获得预期效果。TOBI Podhaler胶囊的内容物仅用于口服吸入,只能与Podhaler装置一起使用。对于6岁及以上的成人和儿科患者,TOBI Podhaler的推荐剂量是使用Podhaler装置吸入四粒28毫克TOBI Podhaler胶囊的内容物,每天两次,持续28天。TOBI Podhaler每天两次,交替给药28天。治疗 28 天后,患者应在接下来的 28 天内停止 TOBI Podhaler 治疗,然后在接下来的 28 天开启和 28 天关闭周期内恢复治疗。TOBI Podhaler胶囊应始终储存在泡罩中,每个胶囊只能在使用前立即取出。对于服用几种不同吸入药物和/或进行胸部物理治疗的患者,治疗顺序应遵循医生的建议。建议TOBI Podhaler最后服用。

不良反应
TOBI Podhaler已在425名暴露于至少一剂TOBI Podhaler的囊性纤维化患者中的安全性进行了评估,其中包括273名在三个周期(6个月)治疗中暴露的患者。每个周期包括28天的治疗(每天两次施用112mg)和28天的治疗。血清肌酐≥2mg/dL和血尿素氮(BUN)≥40mg/dL的患者被排除在临床研究之外。该人群中有218名男性和207名女性,反映了美国的囊性纤维化人群,绝大多数患者是白种人。221岁≥20例,121<13至20岁≥83例,6至<13岁≥239例。有<>例筛查FEV的患者1% 预测 ≥50%,156 例筛查 FEV 患者1% 预测 <50%,30 例患者 FEV 缺失1%预测。主要安全性人群反映了研究1的患者,这是一项开放标签研究,比较TOBI Podhaler与TOBI(妥布霉素吸入溶液,USP)在三个周期内,每次4周,然后停止治疗4周。随机化,按计划的3:2比例,导致308名患者接受TOBI Podhaler治疗,209名患者接受TOBI治疗。对于TOBI Podhaler组和TOBI组,每个周期的平均药物暴露时间为28至29天。两只手臂的平均年龄在25至26岁之间。平均基线有限碳排放值1两组的预测百分比为53%。

Information on the long-term efficacy and safety of TOBI Podhaler is limited. There is no information in patients with limited pulmonary reserve (FEV1 <25% predicted). Decreased susceptibility of Pseudomonas aeruginosa to tobramycin has been seen with use of TOBI Podhaler. The relationship between in vitro susceptibility test results and clinical outcome with TOBI Podhaler therapy is not clear. Occurrence of decreased susceptibility on treatment should be monitored, and treatment with an alternative therapy should be considered if clinical worsening is observed.TOBI Podhaler may not be tolerated by all patients. Patients should be instructed to consider alternative therapy if they are unable to tolerate TOBI Podhaler. Patients should be advised to complete a full 28-day course of TOBI Podhaler, even if they are feeling better. After 28 days of therapy, patients should stop TOBI Podhaler therapy for the next 28 days, and then resume therapy for the next 28-day on and 28-day off cycle.Patients should be advised that if they have been prescribed a 7-day pack of TOBI Podhaler either immediately before or during a 28-day treatment with TOBI Podhaler, then they must count each day of use toward the 28 day on-treatment part of their cycle. Patients should only take a total of 28 consecutive days of treatment during a cycle.Similarly, patients should be advised that if they have been prescribed a 1-day pack of TOBI Podhaler either immediately before or during a 28-day treatment with TOBI Podhaler, then they must count each day of use toward the 28 day on-treatment part of their cycle. Patients should only take a total of 28 consecutive days of treatment during a cycle.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(202372419585116.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 20230725
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15900659515@163.com